表没食子儿茶素没食子酸酯纳米颗粒对大鼠/小鼠阿尔茨海默氏症模型的体内治疗效果:系统综述

IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY DARU Journal of Pharmaceutical Sciences Pub Date : 2023-12-11 DOI:10.1007/s40199-023-00494-8
Maha K. A. Khalifa, Somaia A. Abdel-Sattar, Omnya M. Amin, Neveen A. Kohaf, Heba S. Zaky, Marwa A. Abd El‑Fattah, Kamilia H. A. Mohammed, Noha M. Badawi, Ihab Mansoor, Heba A. Eassa
{"title":"表没食子儿茶素没食子酸酯纳米颗粒对大鼠/小鼠阿尔茨海默氏症模型的体内治疗效果:系统综述","authors":"Maha K. A. Khalifa, Somaia A. Abdel-Sattar, Omnya M. Amin, Neveen A. Kohaf, Heba S. Zaky, Marwa A. Abd El‑Fattah, Kamilia H. A. Mohammed, Noha M. Badawi, Ihab Mansoor, Heba A. Eassa","doi":"10.1007/s40199-023-00494-8","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Alzheimer’s disease (AD) is a neurological disease that causes memory loss over time. Current therapies are limited and frequently inadequate. Epigallocatechin gallate (EGCG), has antioxidant, anti-inflammatory, antifibrosis, anti-remodeling and tissue-protective qualities that may be effective in treatment of different diseases, including AD. Because of nanoparticles’ high surface area, they can enhance solubility, stability, pharmacokinetics and biodistribution, and diminish toxicities. Besides, lipid nanoparticles have a high binding affinity that can enhance the rate of drug transport across BBB. So, EGCG nanoparticles represent a promising treatment for AD.</p><h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>This systematic review sought to assess the efficacy of EGCG nanoparticles against AD in rat/mouse models.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Study was conducted in accordance with PRISMA guidelines, and the protocol was registered in PROSPERO. Electronic databases were searched to discover relevant studies published up to October 2022.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Two studies met the inclusion criteria out of 1338 and were included in this systematic review. Collectively, the results indicate that EGCG has a significant potential for reducing AD pathology and improving cognitive deficits in rat/mouse models. The formulated particles were in the nanometer range, as indicated by TEM, with good particle size control and stability. EGCG nanoparticles showed superior pharmacokinetic characteristics and improved blood-brain barrier permeability, and increased brain bioavailability compared to free EGCG. Additionally, nanoEGCG were more effective in modulating oxidative stress than free formulation and decreased AChE in the cortex and hippocampus of AlCl3-treated rats.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This systematic analysis of the two studies included showed that EGCG nanoparticles are efficacious as a potential therapeutic intervention for AD in rat/mouse models. However, limited number of studies found indicates insufficient data in this research point that requires further investigation by experimental studies.</p><h3 data-test=\"abstract-sub-heading\">Graphical abstract</h3>\n","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"49 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer’s disease in a rat/mouse model: a systematic review\",\"authors\":\"Maha K. A. Khalifa, Somaia A. Abdel-Sattar, Omnya M. Amin, Neveen A. Kohaf, Heba S. Zaky, Marwa A. Abd El‑Fattah, Kamilia H. A. Mohammed, Noha M. Badawi, Ihab Mansoor, Heba A. Eassa\",\"doi\":\"10.1007/s40199-023-00494-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Background</h3><p>Alzheimer’s disease (AD) is a neurological disease that causes memory loss over time. Current therapies are limited and frequently inadequate. Epigallocatechin gallate (EGCG), has antioxidant, anti-inflammatory, antifibrosis, anti-remodeling and tissue-protective qualities that may be effective in treatment of different diseases, including AD. Because of nanoparticles’ high surface area, they can enhance solubility, stability, pharmacokinetics and biodistribution, and diminish toxicities. Besides, lipid nanoparticles have a high binding affinity that can enhance the rate of drug transport across BBB. So, EGCG nanoparticles represent a promising treatment for AD.</p><h3 data-test=\\\"abstract-sub-heading\\\">Objectives</h3><p>This systematic review sought to assess the efficacy of EGCG nanoparticles against AD in rat/mouse models.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>Study was conducted in accordance with PRISMA guidelines, and the protocol was registered in PROSPERO. Electronic databases were searched to discover relevant studies published up to October 2022.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>Two studies met the inclusion criteria out of 1338 and were included in this systematic review. Collectively, the results indicate that EGCG has a significant potential for reducing AD pathology and improving cognitive deficits in rat/mouse models. The formulated particles were in the nanometer range, as indicated by TEM, with good particle size control and stability. EGCG nanoparticles showed superior pharmacokinetic characteristics and improved blood-brain barrier permeability, and increased brain bioavailability compared to free EGCG. Additionally, nanoEGCG were more effective in modulating oxidative stress than free formulation and decreased AChE in the cortex and hippocampus of AlCl3-treated rats.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusion</h3><p>This systematic analysis of the two studies included showed that EGCG nanoparticles are efficacious as a potential therapeutic intervention for AD in rat/mouse models. However, limited number of studies found indicates insufficient data in this research point that requires further investigation by experimental studies.</p><h3 data-test=\\\"abstract-sub-heading\\\">Graphical abstract</h3>\\n\",\"PeriodicalId\":10888,\"journal\":{\"name\":\"DARU Journal of Pharmaceutical Sciences\",\"volume\":\"49 1\",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"DARU Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40199-023-00494-8\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"DARU Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40199-023-00494-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景阿尔茨海默病(AD)是一种神经系统疾病,会导致记忆力逐渐减退。目前的治疗方法有限,而且常常不充分。表没食子儿茶素没食子酸酯(EGCG)具有抗氧化、抗炎、抗纤维化、抗重塑和保护组织的作用,可有效治疗包括阿兹海默症在内的各种疾病。由于纳米颗粒具有高比表面积,因此可以提高溶解度、稳定性、药代动力学和生物分布,减少毒性。此外,脂质纳米颗粒具有很高的结合亲和力,可以提高药物通过 BBB 的转运速度。本系统综述旨在评估 EGCG 纳米颗粒在大鼠/小鼠模型中对 AD 的疗效。结果在 1338 项研究中,有 2 项符合纳入标准,被纳入本系统综述。研究结果表明,EGCG在减少AD病理变化和改善大鼠/小鼠模型认知障碍方面具有显著的潜力。根据 TEM 显示,配制的颗粒在纳米范围内,具有良好的粒度控制和稳定性。与游离 EGCG 相比,EGCG 纳米颗粒显示出更优越的药代动力学特性,改善了血脑屏障渗透性,提高了脑生物利用率。此外,与游离制剂相比,纳米 EGCG 能更有效地调节氧化应激,并能降低 AlCl3 处理大鼠皮层和海马中的 AChE。然而,有限的研究数量表明该研究点的数据不足,需要通过实验研究进行进一步调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer’s disease in a rat/mouse model: a systematic review

Background

Alzheimer’s disease (AD) is a neurological disease that causes memory loss over time. Current therapies are limited and frequently inadequate. Epigallocatechin gallate (EGCG), has antioxidant, anti-inflammatory, antifibrosis, anti-remodeling and tissue-protective qualities that may be effective in treatment of different diseases, including AD. Because of nanoparticles’ high surface area, they can enhance solubility, stability, pharmacokinetics and biodistribution, and diminish toxicities. Besides, lipid nanoparticles have a high binding affinity that can enhance the rate of drug transport across BBB. So, EGCG nanoparticles represent a promising treatment for AD.

Objectives

This systematic review sought to assess the efficacy of EGCG nanoparticles against AD in rat/mouse models.

Methods

Study was conducted in accordance with PRISMA guidelines, and the protocol was registered in PROSPERO. Electronic databases were searched to discover relevant studies published up to October 2022.

Results

Two studies met the inclusion criteria out of 1338 and were included in this systematic review. Collectively, the results indicate that EGCG has a significant potential for reducing AD pathology and improving cognitive deficits in rat/mouse models. The formulated particles were in the nanometer range, as indicated by TEM, with good particle size control and stability. EGCG nanoparticles showed superior pharmacokinetic characteristics and improved blood-brain barrier permeability, and increased brain bioavailability compared to free EGCG. Additionally, nanoEGCG were more effective in modulating oxidative stress than free formulation and decreased AChE in the cortex and hippocampus of AlCl3-treated rats.

Conclusion

This systematic analysis of the two studies included showed that EGCG nanoparticles are efficacious as a potential therapeutic intervention for AD in rat/mouse models. However, limited number of studies found indicates insufficient data in this research point that requires further investigation by experimental studies.

Graphical abstract

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
DARU Journal of Pharmaceutical Sciences
DARU Journal of Pharmaceutical Sciences PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
0
期刊介绍: DARU Journal of Pharmaceutical Sciences is a peer-reviewed journal published on behalf of Tehran University of Medical Sciences. The journal encompasses all fields of the pharmaceutical sciences and presents timely research on all areas of drug conception, design, manufacture, classification and assessment. The term DARU is derived from the Persian name meaning drug or medicine. This journal is a unique platform to improve the knowledge of researchers and scientists by publishing novel articles including basic and clinical investigations from members of the global scientific community in the forms of original articles, systematic or narrative reviews, meta-analyses, letters, and short communications.
期刊最新文献
Royal jelly and its hormonal effects in breast cancer: a literature review. Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles. Comparative evaluation of different oral iron salts in the management of iron deficiency anemia. Prediction of naloxone dose in opioids toxicity based on machine learning techniques (artificial intelligence). Effect of the treatment of iron deficiency anemia on chronic drug-resistant cough: a rare case report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1